US 12,331,357 B2
Methods for assessing risk of developing a viral disease using a genetic test
Eli Hatchwell, Winchester (GB); Peggy S. Eis, Fitchburg, WI (US); Edward B. Smith, III, New York, NY (US); and Yassine Taoufik, Paris (FR)
Assigned to PML Screening, LLC, Newport Beach, CA (US); The Université Paris-Saclay, Gif-sur-Yvette (FR); The Assistance Publique—Hòpitaux de Paris (APHP), Paris (FR); and The Institut National de la Santé et de la Recherche Medicale (INSERM), Paris (FR)
Filed by PML Screening, LLC, Newport Beach, CA (US); The Assistance Publique—Hôpitaux de Paris (APHP), Paris (FR); The Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR); and The Université Paris-Saclay, Saint Aubin (FR)
Filed on Jan. 5, 2021, as Appl. No. 17/141,885.
Application 17/141,885 is a division of application No. 16/245,849, filed on Jan. 11, 2019, granted, now 10,941,448.
Application 16/245,849 is a continuation of application No. 15/639,591, filed on Jun. 30, 2017, granted, now 10,240,205, issued on Mar. 26, 2019.
Claims priority of provisional application 62/524,324, filed on Jun. 23, 2017.
Claims priority of provisional application 62/454,676, filed on Feb. 3, 2017.
Prior Publication US 2021/0371928 A1, Dec. 2, 2021
Int. Cl. C12Q 1/6883 (2018.01); C07K 16/28 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C12Q 1/6883 (2013.01) [C07K 16/2839 (2013.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/025 (2013.01); G01N 2800/065 (2013.01); G01N 2800/285 (2013.01); G01N 2800/52 (2013.01)] 58 Claims
 
1. A method of treating a condition in a subject in need of an immunosuppressive medication comprising: administering to the subject a therapeutically effective amount of an immunosuppressive medication that has a potential to induce progressive multifocal leukoencephalopathy (PML) due to an infection of the brain by John Cunningham virus (JCV), wherein the subject has been tested for a presence of one or more genetic variations with a genetic assay and has been identified as not having the one or more genetic variations,
wherein:
(i) the one or more genetic variations is an insertion, a deletion, or a base substitution in a gene selected from the group consisting of a PRKDC gene, a ZAP70 gene, a RAG1 gene, an IRAK4 gene, a PLCG2 gene, a TLR3 gene, a CHD7 gene, a GATA2 gene, a STIM1 gene, an IFIH1 gene, a TBK1 gene, a CARD11 gene, an ATR gene, a RIPK3 gene, or a LYST gene; or
(ii) the one or more genetic variations comprise chr9: 286491 G>A, chr9: 286593 C>A, chr9: 304628 G>A, chr9: 312134 G>A, chr9: 328047 T>A, chr9: 334277 G>A, chr9: 368128 C>T, chr9: 446401 A>G, chr4: 103522068 A>G, chr4: 103522150 G>A, or chr4: 103528328 C>T, wherein chromosome positions of the one or more genetic variations are defined with respect to UCSC hg19; and
wherein:
(A) the subject has been tested with a JCV antibody test, a CD62L test or a CSF IgM oligoclonal bands test, or (B) the condition is Crohn's disease, multiple sclerosis, or a relapsing form of multiple sclerosis.